<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practice
Marie-Christine Étienne-Grimaldi(Centre Antoine Lacassagne), Chantal Le Guellec(Centre Hospitalier Universitaire de Tours), Fabienne Thomas(Institut Claudius Regaud), Régis Bouquié(Centre d'Investigation Clinique de Nantes), Marie‐Pierre Gaub(Laboratoire de Biochimie), Marie‐Anne Loriot(Inserm), Nicolas Picard(Université de Limoges), Laurent Philibert(Institut de Recherche en Cancérologie de Montpellier), Delphine Poncet(Université Claude Bernard Lyon 1), Franck Broly(Université Lille Nord de France), Valérie Le Morvan(Inserm), Cécile Ged(Centre Hospitalier Universitaire de Bordeaux), Céline Narjoz(Délégation Paris 5), Sylvie Quaranta(Hôpital de la Timone), Marie‐Claude Gagnieu(Hôpital Edouard Herriot), François Ghiringhelli(Inserm), Jean‐Christophe Boyer(Centre Hospitalier Universitaire de Nîmes)
Cited by 110
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells
|Journal of Clinical Investigation|2010|985
CD4<b>+</b>CD25<b>+</b> regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner
|The Journal of Experimental Medicine|2005|918
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Classification of current anticancer immunotherapies
|Oncotarget|2014|469